Ernexa's ERNA-101 Achieves 100% Survival, Complete Tumor Elimination in Ovarian Cancer Preclinical Models
ERNA sits 90% above its 52-week low of $3.183.
Summary
Ernexa Therapeutics announced breakthrough preclinical results for its lead cell therapy candidate, ERNA-101, demonstrating 100% survival and complete tumor elimination in syngeneic ovarian cancer models when combined with PD-1 blockade. This highly positive data, which also showed remodeling of the tumor microenvironment, comes as the micro-cap company recently executed a 1-for-25 reverse stock split to regain Nasdaq compliance and faces ongoing concerns about delisting and its ability to continue as a going concern. For a company with significant financial challenges, these exceptionally strong preclinical findings for a lead asset could be a critical catalyst, potentially attracting investor interest and facilitating future clinical development and financing efforts. Traders will be watching for the company's progress in advancing ERNA-101 towards a first-in-human clinical trial and subsequent clinical data.
At the time of this announcement, ERNA was trading at $6.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $3.18 to $100.46. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.